Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | TPH1 | P17752 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | FAP | Q12884 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309076 | 1.00 | LDHA (0.59) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1311287 | 1.00 | LDHA (0.59) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL5934842 | 0.98 | LDHA (0.57) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL7301098 | 0.98 | LDHA (0.57) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL5934840 | 0.98 | LDHA (0.57) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Iodide SCHEMBL28191565 | 0.97 | LDHA (0.56) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL28190903 | 0.97 | LDHA (0.56) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL539240 | 0.95 | LDHA (0.54) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL539241 | 0.95 | LDHA (0.54) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL540603 | 0.94 | TPH1 (0.54) | LDHASLC6A4CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109251163-B | Resolution method of indoline-2-formic acid compound and intermediate thereof | 江苏永达药业有限公司 | 2022-12-27 | — | — | CN | claimed |
| CN-109251163-A | A kind of method for splitting of indoline -2- formic acid compound and wherein mesosome | 江苏永达药业有限公司 | 2019-01-22 | — | — | CN | claimed |
| WO-2025032242-A1 | COMPOUNDS AND USES | UNIVERSITEIT LEIDEN (NL) | 2025-02-13 | — | — | WO | disclosed |
| CN-109251163-B | Resolution method of indoline-2-formic acid compound and intermediate thereof | 江苏永达药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| CN-113692401-A | Process for producing aromatic amino acid derivative | 中外制药株式会社 | 2021-11-23 | — | — | CN | disclosed |
| US-11040939-B1 | N-transfer reagent and method for preparing the same and its application | NATIONAL CHENG KUNG UNIVERSITY (TW) | 2021-06-22 | — | — | US | disclosed |
| WO-2020189540-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | 中外製薬株式会社 | 2020-09-24 | — | — | WO | disclosed |
| CN-109251163-A | A kind of method for splitting of indoline -2- formic acid compound and wherein mesosome | 江苏永达药业有限公司 | 2019-01-22 | — | — | CN | disclosed |
| CN-104860924-B | Melanocortin-4 receptor modulators prepare their method and its purposes in human medicine and cosmetics | 盖尔德马研究及发展公司 | 2018-10-09 | — | — | CN | disclosed |
| CN-104387372-B | Oxo azetidine derivatives, preparation method and its purposes in human medical and cosmetics | 盖尔德马研究及发展公司 | 2018-06-26 | — | — | CN | disclosed |
| CN-108164583-A | Proteasome inhibitor and its application | 珠海诺贝尔国际生物医药研究院有限公司 | 2018-06-15 | — | — | CN | disclosed |
| US-8080576-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080545-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-6423689-B1 | Peptidyl calcium channel blockers | WARNER-LAMBERT COMPANY | 2002-07-23 | — | — | US | disclosed |
| CN-1272841-A | Novel lactam metalloprotease inhibitors | DU PONT PHARM CO (US) | 2000-11-08 | — | — | CN | disclosed |
| WO-1989010751-A1 | FUNCTIONALIZED PEPTIDYL AMINODIOLS AND -TRIOLS | ABBOTT LABORATORIES (US) | 1989-11-16 | — | — | WO | disclosed |
| EP-0341602-A2 | Renin-inhibiting functionalized peptidyl aminodiols and - triols | ABBOTT LABORATORIES (US) | 1989-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040939-B1 | N-transfer reagent and method for preparing the same and its application | DNTT, NNMT, NMT1 | LDHA 1417/4885SLC6A4 355/4885CYP1A2 547/4885 |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | LDHA 3817/4885SLC6A4 4815/4885CYP1A2 1716/4885 |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | LDHA 3817/4885SLC6A4 4815/4885CYP1A2 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.